WHY IT MATTERS: As federal rescheduling moves forward, organizations that center both clinical evidence and patient experience could directly shape whether patients gain broader, safer, and more affordable access to cannabinoid therapies. CLINICAL OVERVIEW: A newly formed cannabis medicine group is working to ensure that federal policy discussions around cannabinoid therapy are rooted in scientific evidence and shaped by real patient perspectives. This effort comes at a critical moment as rescheduling conversations advance at the federal level, creating an opening to influence how cannabis is regulated, researched, and integrated into clinical care.
Cannabis Use in Older Adults Is Rising—Now What?
Older adults are turning to cannabis in record numbers—but you wouldn’t know it from most medical offices. This isn’t a rebellion—it’s a quiet referendum on how we handle chronic illness, aging, and autonomy. The question isn’t whether it’s happening—the question is: where are the doctors?